<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245437</url>
  </required_header>
  <id_info>
    <org_study_id>OT R33</org_study_id>
    <nct_id>NCT03245437</nct_id>
  </id_info>
  <brief_title>Target Engagement and Response to Oxytocin</brief_title>
  <official_title>Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure whether the engagement of intranasal oxytocin with a brain target is
      related to effects on learning during a social cognition training program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will determine whether oxytocin (OT) administration 30 min before a training
      session enhances the learning of social information in the context of a social cognitive
      skills training (SCST) program, and it will test a possible mediator of this effect. Subjects
      with psychotic disorders will be randomized to one of four groups in a 2 by 2 factorial
      design: OT with SCST; Placebo with SCST; OT with training control condition; placebo with
      training control condition. Target engagement will be measured in an OT challenge (placebo
      versus OT one week apart) prior to baseline assessment. The measure of target engagement will
      be EEG mu suppression while observing biological motion. A social cognition battery will be
      administered at baseline, at midpoint after 6 weeks of SCST, and at completion of training at
      12 weeks. The battery will include measures of social cue identification and mentalizing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Social Cognition Composite Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>We will assess social cognition in two subdomains: (1) social cue identification (Managing Emotions component of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) branch 1, Ekman, Profile of Nonverbal Sensitivity (PONS); and (2) mentalizing (The Awareness of Social Inference Test (TASIT). and Empathic accuracy) (see below). The primary summary measure for each test will be mean-centered and standardized to create a Z-score. These Z-scores will be averaged to create a single composite score for social cognition that will serve as the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite score of non-social cognition from the MATRICS Consensus Cognitive Battery</measure>
    <time_frame>16 weeks</time_frame>
    <description>Standardized z-score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Oxytocin with SCST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin with SCST (active condition)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin with Health Management</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Administration of OT with control psychosocial treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with SCST</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Placebo with active psychosocial treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with HM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Placebo with control psychosocial treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>Oxytocin with SCST</arm_group_label>
    <arm_group_label>Oxytocin with Health Management</arm_group_label>
    <other_name>OT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social Cognition Skills Training</intervention_name>
    <description>Group based training in social cognition skills</description>
    <arm_group_label>Oxytocin with SCST</arm_group_label>
    <arm_group_label>Placebo with SCST</arm_group_label>
    <other_name>SCST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health Management</intervention_name>
    <description>Group-based training in mental health management</description>
    <arm_group_label>Oxytocin with Health Management</arm_group_label>
    <arm_group_label>Placebo with HM</arm_group_label>
    <other_name>HM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>placebo condition</description>
    <arm_group_label>Placebo with SCST</arm_group_label>
    <arm_group_label>Placebo with HM</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia or schizoaffective disorder

          -  stable on an antipsychotic medication

        Exclusion Criteria:

          -  positive pregnancy test history of head injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Stephen R. Marder</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Social Cognition</keyword>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

